Amp, the dude created an alias yesterday specifically to post about a follow-up lawsuit to one that already was settled, and then mark the post "strong sell." So, you can see where he's coming from.
Case settled: Seattle Genetics, Inc. v. Arizona Technology Enterprises et al
Represented Seattle Genetics in three related disputes involving claims of breach of contract, breach of license and patent infringement. At issue was an FDA-approved method for delivering targeted cancer therapy to patients. After vigorous litigation in three different jurisdictions, the case settled quite favorably.
Seattle Genetics, Inc. v. Arizona Technology et al, No. 2:12-cv-01732 (W.D. Wash. filed Oct. 5, 2012); The Arizona Board of Regents v. Seattle Genetics, American Arbitration Assn. No. 76 122 00220 12; The Arizona Board of Regents v. Seattle Genetics, Arizona Superior Court, Maricopa County, No. CV2012-016700.
Amp, it's futile. A waste of electrons. We've seen this show many times before. It goes up steadily as the players play and commissions are earned; it goes down from time to time as the players play, the easily manipulated are manipulated, the worriers worry, and commissions are earned. But it pretty much returns to its base right around here, and it remains the same solid company with the same promising future.
Sometimes, stocks go up for no apparent reason. Sometimes. they go down for no apparent reason. If you like SGEN long-term - and you should - day to day fluctuations don't matter a bit.
Stoopid Yahoo system won't let me post the rest. If you want to see it, go to SeekingAlpha and punch SGEN into the search box.
Anything on Seeking Alpha always should be taken with a grain of salt. That said, this seems reasonably on the mark, imo:
Stephen Simpson, CFA, Kratisto Investing
Amidst some safety and competition concerns, Seattle Genetics is gearing up for an important clinical update - the Phase III results of the AETHERA study in post-transplant patients.
Label extensions could nearly triple the value of Adcetris, with follow-on studies offering important risk reduction events.
About three-quarters of my estimate of Seattle Genetics' value is tied to Adcetris, but early-stage pipeline compounds do have some exciting potential.
Oncology biotech Seattle Genetics (NASDAQ:SGEN) has had a bit of an interesting ride since I reviewed the company's prospects and valuation back in December. The shares moved up about 40% through February of this year on optimism for the company's deep portfolio of antibody drug conjugate (or ADC) compounds, not to mention biotech enthusiasm in general, before getting caught up in the great biotech washout and fears tied to the safety of lead drug Adcetris and changes to clinical trials. Add in some concerns about competition from immuno-oncology drugs and there's a lot to digest. When it is all said and done, not all that much has changed on a "net basis" in my view - Seattle Genetics doesn't look as compelling on a value basis, but there's significant upside if clinical trial read-outs de-risk the pipeline....
The Bakers are insiders and big percentage holders. If they were buying again, they would have to report the buys promptly, and thus far no reports have been filed.
...this was just posted on a Hodgkin's patient message board:
[Name redacted] 1 hr · Westland, MI · Two rounds of Brentuximab and the hodge is 80% gone!
Terry: Typically, this is not an overly active Yahoo board - one of the few that becomes active only as required by events and one of the few that has actively discouraged the presence of trolls. I believe the relative silence here lately is in response to two factors: 1. Nothing newsworthy or comment-worthy has occurred recently regarding SGEN. 2. Rickarooski and his many aliases have sucked up what little oxygen has existed here lately.
This is likely to change Thursday when earnings are released and the conference call is held. Still, I wouldn't expect any particularly ground-breaking developments or news. For a biotech as promising as SGEN, the best you can hope for at this stage is "steady as she goes." And, through their recent additional purchases, the Bakers are telling us that matters seem to be progressing rather well.
Atpl, that's Rickarooski's style when he trolls under his Maui alias - a seemingly balanced post that ends up being subtly negative. He uses a different style and 'voice' for each of his many aliases. A very ill puppy, but one of the more creative trolls on the Yahoo message boards. Fstout57 is another of Rickarooski's aliases - one of the tells on a troll: They tell you about their imaginary low buys at the same time they tell you about their imaginary profitable sales.
This guy is just a garden variety troll, and not a very smart one, and very possibly just another one of Ricky's aliases. He's cherry picking examples that have nothing to do with SGEN and its assets, technology and pipeline. You're better off simply ignoring him, which is my plan going forward.